23.3 C
Vientiane
Monday, November 10, 2025
spot_img
Home Blog Page 2004

Rizhao embraces maritime development for future growth

RIZHAO, China, Feb. 19, 2025 /PRNewswire/ —  A news report from chinadaily.com.cn:

Rizhao, located in East China’s Shandong province, is advancing the high-quality integration of its port, industry, and city, charting a course towards a new paradigm of comprehensive development.

Building on its rich maritime heritage and commitment to sustainable growth, Rizhao is entering a transformative phase. By enhancing port capabilities, fostering a robust industrial ecosystem along its shores, and establishing itself as a key gateway for both domestic and international connectivity, Rizhao is expanding opportunities for a thriving port, vibrant industries, and dynamic urban centers. This comprehensive approach is setting the stage for future growth.

Strategic support from provincial and municipal authorities underscores the pivotal role of Rizhao and Rizhao Port in national and regional development. Rizhao Port is the only port in China with railway connections spanning 2,000 kilometers directly linked to its port area. The port is leveraging its intermodal train services, shifting from bulk cargo handling to containerized operations. It is pioneering coal and coke intermodal train services that streamline logistics and reduce transportation costs for clients.

With the port at its core, industry as its engine, and the city as its foundation, Rizhao is rallying collective efforts to strengthen port development, industrial growth, and urban vitality. By collaborating with various stakeholders, districts, counties, and functional port-city areas, Rizhao Port is actively attracting investment and unlocking the value of shoreline resources. Entities within Shandong Port Group are contributing to the city’s evolution, facilitating the deep integration of industrial activities with urban functions, and further expanding opportunities.

The integration of port, production, and urban development represents a holistic and long-term endeavor, a cornerstone strategy for propelling Rizhao towards a new era of economic and social advancement. Through dedicated on-site teams and proactive service enhancements by municipal departments, districts, counties, and functional areas, Rizhao is embracing a collaborative approach, fostering mutual engagement, and nurturing a culture of shared progress. Ultimately, the city is poised to enter a new era of integrated development across its port, production, and urban sectors.

RSMC Asia Tour 1-on-1 Consultation Event, Supporting Diverse Families in Achieving Their Fertility Dreams

HONG KONG and TAIPEI, Feb. 19, 2025 /PRNewswire/ — On the eve of International Women’s Day, RSMC(Reproductive Sciences Medical Center), a leading global fertility institution based in California, USA, announced that from March 8th to 16th, it will offer free physician consultations in multiple cities across Asia. Leveraging over 30 years of experience in infertility treatment, RSMC once again demonstrates its support for women’s reproductive autonomy.

Additionally, American IVF services are not limited by marital status or sexual orientation, providing RSMC with greater flexibility in meeting the fertility needs of diverse families. For instance, in Taiwan, the first place in Asia to legalize same-sex marriage, we have successfully helped the popular lesbian influencer couple, “Rabbit and Wolf,” realize their dream of having a pair of children!

The success rate of American IVF is among the highest in the world, and RSMC boasts a frozen egg recovery rate and PGS embryo pass rate that surpass the national average. Having assisted over 20,000 families in achieving their dreams of parenthood, RSMC offers a comprehensive, multilingual, and real-time consultation team. Beyond providing professional medical services, RSMC also offers value-added services such as international embryo and gamete transport, legal and insurance support, postpartum care centers, and assistance in bringing babies back to their home countries, attracting numerous Asian patients to seek treatment in the U.S.

If you are interested in our services, we welcome you to schedule a free in-person consultation with our American medical director (Include Taipei, Beijing, and Shenzhen) or book a free online consultation. For appointments, please contact us via Line/WeChat: rsmctw (WhatsApp: +1 858-342-6046).

Traditional Chinese Website|English Website|Japanese Website|Simplified Chinese official website

Contact Us
Line: rsmctw
WhatsApp: +1 858-342-6046
Wechat: rsmctw
Email: rsmctw@fertile.com.hk

DigiFT Collaborates with Invesco on Tokenized Solution

1.    DigiFT is collaborating with Invesco to offer a tokenized solution for accredited and institutional investors on DigiFT Singapore’s platform to get access to one of Invesco’s private credit strategies.
2.    It is the first and only token out of Singapore with daily trading that offers access to a private credit strategy. 

SINGAPORE, Feb. 19, 2025 /PRNewswire/ — DigiFT, a licensed on-chain exchange in Singapore is delighted to announce that the platform will offer a DigiFT token which will invest in Invesco’s private credit strategies.

DigiFT’s tokens will be available to accredited and institutional investors via DigiFT and accepts subscriptions and redemptions in fiat currencies like USD, and stablecoins like USDC and USDT. The strategy targets to provide a high level of current income, consistent with the preservation of capital, by investing primarily in senior secured loans to companies with stable operating profiles, dependable cash flow generation and strong asset coverage. 

According to RWA.xyz, private credit is the most popular alternative asset class, accounting for 68% of tokenized real-world assets, outpacing even tokenized US Treasury Securities like T-Bills. This trend could continue as US Treasury rates are expected to come down from recent highs.

As RWAs continue to grow in popularity, DigiFT aims to be the preferred partner to leading institutional players. DigiFT was also recently appointed as an authorized distribution partner for another global asset manager in launching their first tokenized money market fund.  

“We believe that working with the best teams, to bring the best in-class assets on-chain is more important than being the first to market. To bring truly institutional-grade assets on-chain requires nothing less than having the best partners in the business like Invesco,” said Henry Zhang, Founder & Chief Executive Officer of DigiFT. 

“On the back of rapid developments in distributed ledger technology, fund tokenization is one of the most remarkable trends. Many advantages of this innovation are finding a new home in the asset management space, transforming the industry. We are excited that an innovative platform like DigiFT is offering this solution, opening up more investment opportunities for investors,” said Noelle Lim, Invesco’s CEO of Singapore and Head of Private Banks, Asia ex Japan.  
 
DigiFT has also partnered with custodians like Copper, Komainu, Rakkar, and Zodia to provide seamless access to its tokenized RWAs for Web3 asset managers and owners such as hedge funds, buy-side trading firms, and DAO treasury managers.  
 
DigiFT is actively seeking to partner with more issuers, DeFi protocols, dApps, and other Web3 protocols to enable users across different blockchains to access institutional-grade RWA yields on-chain. 

About DigiFT (www.digift.sg

DigiFT is the first regulatory-compliant exchange for on-chain real-world assets to be licensed by the Monetary Authority of Singapore as a Recognised Market Operator and Capital Markets Services provider. DigiFT enables asset owners, particularly financial institutions, to issue blockchain-based security tokens that investors can trade with continuous liquidity using an Automated Market Maker (AMM). 

About Invesco 

Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life. NYSE: IVZ; www.invesco.com.  

Disclaimer: DigiFT and/or its subsidiaries endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon information contained on this article. Before making any investment decision, please seek independent legal and financial advice.  

Polyshine Solar Unveils New Generation of Lightweight Flexible PV Modules at World Smart Energy Week 2025

TOKYO, Feb. 19, 2025 /PRNewswire/ — February 19, 2025 at the opening of Japan’s World Smart Energy Week 2025, Polyshine Solar captivated global attention with its revolutionary lightweight flexible photovoltaic modules. Designed to redefine rooftop solar adoption worldwide, the product combines ultra-lightweight engineering, easy installation, and a 25-year performance guarantee, empowering households and businesses to utilize clean energy.

Visitors explore Polyshine Solar's booth at Japan’s World Smart Energy Week 2025
Visitors explore Polyshine Solar’s booth at Japan’s World Smart Energy Week 2025

Key Innovations

  1. 70% Weight Reduction: Utilizing patented polymer encapsulation technology, the modules achieve a remarkable weight reduction of 70% compared to traditional glass-based panels (as light as 2.92 kg/㎡). With a bending radius of 0.5 meters, they eliminate installation barriers for curved surfaces or low-load-bearing structures, requiring zero retrofitting costs.
  2. Easy Installation: Featuring peel-and-stick adhesion or strap-fastening options, the system enables rapid, secure deployment of distributed solar stations, making green energy accessible in minutes.
  3. Global Compliance: Certified by TUV, CQC, CE, and other international authorities, the product meets diverse energy transition needs across markets.

Product Lineup

  • Commercial & Industrial Rooftop Series: Seamlessly adheres to curved or low-load roofs without drilling or mounting frames.
  • Balcony Solar Solutions: Integrated grommets and Velcro straps allow DIY installation, transforming urban spaces into micro power plants.

Driving the Energy Transition
Polyshine Solar represents not just a product but a paradigm shift. By simplifying solar installation to “stick-and-generate” ease, it democratizes access to renewable energy. At the exhibition, the company received over 2,000 inquiries, underscoring its transformative potential. Moving forward, Polyshine Solar plans global deployment of its systems, turning underutilized rooftops into clean energy assets and empowering every building owner to contribute to sustainable development.

Visitors explore Polyshine Solar's booth at Japan’s World Smart Energy Week 2025
Visitors explore Polyshine Solar’s booth at Japan’s World Smart Energy Week 2025

 

Hong Kong to Host Landmark International Symposium on Genomic Medicine

HKGI Partners with Global Leaders to Chart a Course for Healthcare Transformation

HONG KONG, Feb. 19, 2025 /PRNewswire/ — Genomic medicine has been gaining global prominence for its vast potential to revolutionise healthcare services. In the case of rare conditions, genomic medicine has been particularly transformative, as approximately 80% of rare diseases are of genetic origin. Genomic medicine has the power to facilitate diagnosis and access to curative and life-changing treatments for people living with these rare conditions. Now, Hong Kong is set to partner with world-renowned authorities to drive exchanges dedicated to this burgeoning field, taking advantage of the city’s unique strengths in medical research and development.

The Hong Kong Genome Institute (HKGI), Rare Diseases International (RDI), and The Lancet Commission on Rare Diseases (LCRD) will join forces for the first time to organise the International Genomic Medicine Symposium (Symposium) on 17 November 2025 (Monday) at the Hong Kong Science Park. This landmark event will convene distinguished experts, clinicians and scientists from over 20 countries and regions to foster knowledge exchanges in genomic medicine and rare diseases, representing a significant collaboration among leading institutions committed to accelerating the development of genomic medicine on a global scale and providing an unparalleled opportunity to improve outcomes for the 300 million persons living with a rare disease worldwide.

The Symposium, focusing on the latest advancements and trends in genomic medicine, features a robust lineup of local and international experts in genetics and genomics, including Dr Chloe Wilson, Senior Medical Editor of The Lancet, one of the world’s most authoritative academic journals. This diverse group of experts is poised to exchange insights on a wide range of topics – from rare diseases to cancer detection and molecular diagnoses; from genomic data sharing to legal and ethical discussions; and from artificial intelligence (AI) to healthcare record management and scientific research.

The Opening Ceremony will be officiated by Professor Lo Chung-mau, Secretary for Health of the Hong Kong SAR Government. Setting the stage, Professor Lo will deliver a keynote address, laying the groundwork for a deep dive into genomic innovations and clinical applications. Dr Lo Su-vui, Chief Executive Officer of HKGI, and Alexandra Heumber Perry, Chief Executive Officer of RDI, will also join the Opening Ceremony to unveil the event.

Highlights of esteemed speakers include:

  • Professor Dennis Lo, Vice-Chancellor and President of The Chinese University of Hong Kong, as well as Board Member of HKGI, will discuss cutting-edge applications of plasma DNA analysis.
  • Dr Brian Chung, Chief Medical and Scientific Officer of HKGI, will share the journey of implementing Hong Kong Genome Project, the city’s first large-scale whole genome sequencing (WGS) initiative aimed at propelling personalised medicine forward.
  • Professor Zhang Shuyang, President of the Peking Union Medical College Hospital and pioneer in Mainland China’s rare diseases programmes, will introduce respective models covering teaching, service and research.
  • Professor Kym Boycott from the University of Ottawa (Canada) will focus on molecular pathogenesis of rare diseases that improve patient care and family well-being.
  • Professor Roberto Giugliani from the Federal University of Rio Grande do Sul (Brazil) and a leading researcher in Latin American genetics, will share his perspectives on metabolic disorders.
  • Professor Bartha Maria Knoppers from McGill University (Canada) and an expert in genomics and biotechnology ethics, will discuss legal topics arising from genomic data sharing.
  • Professor Gareth Baynam from the Perth Children’s Hospital (Australia), and Professor Yong Chen from the University of Pennsylvania (USA) will also offer insights on harnessing the latest technologies such as AI for clinical and healthcare records to inspire innovation.

Dr Lo Su-vui, Chief Executive Officer of HKGI said, “We are greatly honoured and excited to partner with RDI and LCRD, two world-leading institutions that share our vision of making genomic medicine available to all for better health and well-being. This Symposium, rich in depth and scope, marks a pivotal milestone in advancing genomic medicine through international collaborations. By bringing together global experts and showcasing Hong Kong’s capabilities in genomic research and clinical applications, we are not only reaffirming our commitment to integrating genomics into routine patient care and inspiring ground-breaking research, but also contributing to Hong Kong’s development as an International Health and Medical Innovation Hub.”

Alexandra Heumber Perry, Chief Executive Officer of RDI added, “We are thrilled to partner with the Hong Kong Genome Institute on this important initiative to advance research on rare diseases and improve outcomes for Persons Living with Rare Diseases (PLWRD) around the world. This Symposium, which will bring together leading experts from more than 20 countries and regions, demonstrates our joint commitment to placing PLWRD at the centre of their own care, and to promoting health equity, human rights and access to treatment for PLWRD. Through the shared dedication and expertise of the experts from the RDI-LCRD and HKGI, we will work to ensure that PLWRD are seen, heard and cared for, no matter where they live.”

The one-day Symposium is anticipated to attract close to 300 participants. For programme details, please refer to the Appendix. Following the Symposium, the annual LCRD Meeting will be held on 18-19 November 2025, which will further strengthen international cooperations in research and development of genomic medicine and rare diseases.

For enquiries about the Symposium, please contact: HKGI (symposium@genomics.org.hk) or RDI-LCRD (lcrd@rarediseasesint.org).

About Hong Kong Genome Institute

The Hong Kong Genome Institute (HKGI), established and wholly owned by the Hong Kong SAR Government, commenced full operations in 2021. With the vision “to avail genomic medicine to all for better health and well-being” and supported by the Health Bureau, HKGI works in close collaboration with the Department of Health, Hospital Authority, medical schools of local universities and other stakeholders to accelerate the development of genomic medicine in Hong Kong along four strategic foci: integrate genomics into medicine, advance research, nurture talents and enhance public genomic literacy.

As the first step towards achieving its vision, HKGI launched the Hong Kong Genome Project (HKGP) in 2021 focusing on diseases and research cohorts that would benefit from whole genome sequencing. They include undiagnosed diseases, hereditary cancers and cases related to genomics and precision health. Being the city’s first large-scale genome sequencing project, HKGP serves as a catalyst to benefit patients and their families with more precise diagnosis and personalised treatment. It also aims to establish genome database of the local population, testing infrastructure and talent pool to address the healthcare needs of Hong Kong in the long run.

For more information, please visit https://hkgp.org/en.

About Rare Diseases International

Rare Diseases International (RDI) is the global alliance of people living with a rare disease of all nationalities across all rare diseases. RDI’s mission is to be a strong common voice on behalf of rare disease patients around the world, to advocate for rare diseases as an international public health priority and to represent its members and enhance their capacities. RDI has more than 120 member organizations from 50 countries, which in turn represent rare disease patient groups in more than 150 countries worldwide. 

For more information, please visit https://www.rarediseasesinternational.org.

About Lancet Commission on Rare Diseases

The RDI-Lancet Commission on Rare Diseases (RDI-LCRD) is a new initiative dedicated to improving the lives of Persons Living with a Rare Disease (PLWRD) globally by generating evidence-informed recommendations that can be implemented in all countries. The RDI-LCRD, chaired by Dr. Roberto Giugliani (Brazil) and Dr. Kym Boycott (Canada) brings together 27 Commissioners from 6 continents with a broad range of expertise, perspectives and experience. The overarching goal of the RDI-LCRD is to use robust data to ignite global action that will amplify the voices of PLWRD and ensure that they are seen, heard, and cared for, no matter where they live.

For more information, please visit http://www.rarediseasescommission.org.

 

International Genomic Medicine Symposium 

17 November 2025, Hong Kong  

Charles K. Kao Auditorium, Hong Kong Science Park

Time

Programme

Speaker

09:00

Keynote

Prof Lo Chung-mau, BBS, JP

Secretary for Health

Hong Kong SAR Government

Hong Kong, China

09:15   Opening Ceremony

Panel 1

09:30

Developing Rare Disease Models in China: Service, Teaching and Research

Prof Zhang Shuyang

President 

Peking Union Medical College Hospital China

10:00

Unraveling Molecular Pathogeneses to Enhance Patient Care and Family Well-being

Prof Kym Boycott

Co-Chair

Lancet Commission on Rare Diseases

Professor of Pediatrics

University of Ottawa

Canada

10:30

Panel Discussion

10:45   Coffee Break

Panel 2

11:15

Insights into Rare Diseases:

Focus on Inborn Errors of Metabolism

Prof Roberto Giugliani

Professor of Genetics

Federal University of Rio Grande do Sul Brazil

11:45

Hong Kong Genome Project Case Sharing (1):

Ending the Diagnostic Odyssey

Hong Kong College of Physicians –

Hong Kong Genome Institute Scholar

Hong Kong, China

12:00

Hong Kong Genome Project Case Sharing (2):

Whole Genome Sequencing Informs Personalised Treatment

Hong Kong Academy of Medicine –Hong Kong Genome Institute Scholar

Hong Kong, China

12:15

Panel Discussion

12:30

Lunch

Panel 3


14:00

Exploring Ethico-legal Issues in

Genomic Data Sharing 

Prof Bartha Knoppers 

Director

Centre of Genomics and Policy

McGill University

Canada

14:30

Hong Kong Genome Project:

Advancing the Genomics Frontier

Dr Brian Chung 

Chief Medical and Scientific Officer

Hong Kong Genome Institute

Hong Kong, China

15:00

Facilitating Drug Development in the

Greater Bay Area International Clinical Trial Institute (GBAICTI)

GBAICTI Representative

Hong Kong, China

15:30

Panel Discussion

Panel 4

15:45

AI in Action:

The Journey from Clinical Record to Personalised Treatment

Prof Gareth Baynam 

Medical Director

Rare Care Centre

Perth Children’s Hospital

Australia 

16:15

Harnessing the Power of Electronic Healthcare Records in Scientific Research and Innovation in Genomic Medicine

Prof Yong Chen

Professor of Biostatistics

University of Pennsylvania

USA

16:45

Panel Discussion

Panel 5

17:00

Publishing at The Lancet

Dr Chloe Wilson 

Senior Medical Editor

The Lancet

17:30

Keynote:

Revolutionising Plasma DNA Analysis in Transforming Non-invasive Testing and Cancer Detection

Prof Dennis Lo, SBS, JP

Vice-Chancellor and President

The Chinese University of Hong Kong

Board Member

Hong Kong Genome Institute

Hong Kong, China

18:00

Panel Discussion

18:15

End of Symposium

 

Enquiry

Hong Kong Genome Institute

www.hkgp.org 

symposium@genomics.org.hk 

  Rare Disease International

  www.rarediseasesinternational.org 

  lcrd@rarediseasesint.org 

 

State Grid Shizuishan Power Supply Company: Enhancing Electrical Services to Facilitate Enterprise Resumption of Work and Production

SHIZUISHAN, China, Feb. 19, 2025 /PRNewswire/ — Following the conclusion of the Spring Festival holiday, enterprises in Shizuishan City, Ningxia have entered a crucial phase for resuming work and production. To ensure a smooth transition back to full operational capacity, State Grid Shizuishan Power Supply Company has proactively implemented comprehensive measures to provide high-quality power services, thereby ensuring reliable electricity supply for local enterprises.

On February 13th, technical personnel from State Grid Shizuishan Power Supply Company conducted thorough inspections at key enterprises such as Ningxia Jinyihui Environmental Protection Technology Co., Ltd. They meticulously examined critical electrical equipment including distribution transformers, switchgear, circuit breakers, and other workshop facilities to guarantee zero-defect operation of all power supply systems.

Mr. Wang Minghui, Director of the Equipment Department at Jinyihui Environmental Protection Technology Co., Ltd., remarked, “This year, our order volume has significantly increased compared to last year, resulting in heavier production schedules and higher power consumption. The proactive door-to-door service provided by the power supply company has greatly alleviated our concerns and ensured that our electricity needs are fully met.”

In response to the rapid increase in power demand and the large number of enterprises resuming operations, State Grid Shizuishan Power Supply Company has adopted multiple strategies. These include conducting nighttime patrols and infrared temperature measurements to prevent overheating-related failures, as well as developing customized power supply solutions tailored to the specific production characteristics and electricity requirements of each enterprise.

Furthermore, the company has established a green channel for expedited power services, offering one-stop comprehensive support. This initiative aims to actively deliver reliable power services and safety assurances to enterprises, meet their new electricity demands upon resuming operations, and maximize policy benefits for suspending electricity use.

Looking ahead, State Grid Shizuishan Power Supply Company will continue to prioritize enterprise visits and safe electricity services, closely monitor the progress of resumption efforts, and provide robust and dependable power support through practical actions.

Breaking the Cycle of Gender-Based Violence in Laos

Breaking the Cycle of Gender-Based Violence in Laos
Breaking the Cycle of Gender-Based Violence in Laos

A Silent Crisis

Gender-based violence (GBV) is one of the most widespread human rights violations worldwide. In Laos, the statistics mirror global trends—about one in three women experience sexual, physical, or emotional violence. Yet, only one in ten seek help from authorities. A culture of silence, deeply ingrained in societal norms and patriarchal values, allows the cycle to continue.

“Many survivors believe violence is just a part of life,” said Rattana Sioutoum, a technical officer at the Counseling and Protection Center for Women and Children in Vientiane. “Changing this mindset is a challenge, but it’s one we must take on.”

Rattana remembers one case vividly. “She was just eight years old when she arrived. Her story is a clear reminder that gender-based violence knows no boundaries—even within the family.”

Noi (name changed for privacy) was one of many survivors who found refuge at the center. Over nearly two years, she slowly recovered her health and confidence. With support, she returned to school and eventually graduated, a proud moment for everyone who helped her along the way.

A Safe Haven for Survivors

Since its establishment in 2006 under the Lao Women’s Union, the UNFPA-supported Counseling and Protection Center for Women and Children has provided a sanctuary for survivors of gender-based violence. No survivor is turned away when seeking help.

The center offers social, mental health, and legal services to women and children in need. In the first nine months of 2024 alone, it provided life-changing support to more than 300 survivors, including 91 under the age of 18. Many were referred by hospitals, the police, or through hotlines and social media.

A Coordinated Response

To break down barriers to support, UNFPA has partnered with the Lao Women’s Union to build a nationwide network of shelters and services. With UNFPA’s backing, six shelters have been established in Vientiane Capital, Bokeo, Bolikhamxay, Champasack, Savannakhet, and Attapeu, offering survivors a safe space and comprehensive care.

Service delivery has improved significantly since 2022. The Lao Women’s Union, working alongside the National Commission for the Advancement of Women, Mothers, and Children, developed and adopted standard operating procedures (SOPs) for health, social, and coordination services. These ensure survivors receive consistent, high-quality care. Combined with the Justice SOPs developed by UNDP, these guidelines promote a survivor-centered approach in hospitals, police stations, and social services—emphasizing compassion, professionalism, and adherence to international standards.

This progress has been made possible with the support of key donors, including the Government of Japan, the Korea International Cooperation Agency (KOICA), the Government of Australia through the Department of Foreign Affairs and Trade (DFAT), and the United Kingdom (UK). Their contributions have helped expand shelter networks and implement SOPs, ensuring survivors in multiple provinces receive the care and support they need.

The Counseling and Protection Center for Women and Children is a testament to the success of this coordinated effort. Survivors are guided through a rehabilitation plan that includes health check-ups, family outreach, mental health counseling, and legal aid. Since 2015, the center has also partnered with Mother and Child Hospital to provide comprehensive medical and psychological support, ensuring survivors face no additional barriers on their path to recovery.

“These SOPs are more than just guidelines—they are a lifeline for victims and the staff who support them,” said Dr. Sengchanh Sivilay, head of Gynecology at Mother and Child Hospital. With UNFPA’s support, she has trained over 60 nurses in handling GBV cases effectively. This training has expanded to provinces such as Attapeu, Bokeo, Bolikhamxay, and Savannakhet, strengthening survivor care across the country.

Looking to the Future

UNFPA is working with the Lao government to tackle the root causes of GBV by empowering men and boys to become advocates for change. Efforts include using data and program evidence to develop new National Action Plans for the Elimination of Violence Against Women and Gender Equality for 2026-2030, aligning with Sustainable Development Goal 5.

Ending GBV is not just about providing support to survivors—it’s about prevention, education, and empowerment. It’s about creating a society where violence is neither tolerated nor ignored and where every individual, from community leaders to family members, plays a role in breaking the cycle.

“Ending gender-based violence starts with awareness and accountability,” said Rattana. “By working together, we can build a future where every woman and child lives free from violence and fear.”

To make this vision a reality, additional support is urgently needed. Expanding the shelter network to ensure every province has at least one safe space for survivors is critical. Strengthening SOP implementation, increasing social behavior change initiatives, and engaging men, boys, and communities in addressing GBV’s root causes are all essential steps forward. With continued investment and collaboration, Laos can ensure that no survivor is left behind—and that prevention efforts keep gaining momentum.

SingHealth and Philips sign MOU to advance digital-first healthcare to future-proof care delivery

  • New partnership set to accelerate digital healthcare transformation in Singapore, with a focus on co-designing and integrating Artificial Intelligence (AI) and predictive data management to improve patient care by 2028
  • Projects under this partnership aim to:

Streamline imaging data workflows by developing a standardized data architecture for better diagnostics and patient outcomes; and
Optimize ICU capacity and workflow efficiency by leveraging advanced monitoring and AI tools to help healthcare staff direct care to the right patient at the right time.

SINGAPORE, Feb. 19, 2025 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and SingHealth, Singapore’s largest public healthcare cluster, today announced a strategic partnership to enhance healthcare delivery through deploying innovative technologies and accelerating the digital transformation of the healthcare landscape in Singapore.

Mr Lawrence Loke, Group Chief Information Officer, SingHealth (left) and Jasper Westerink, Acting Managing Director, Philips APAC (right) sign on strategic partnership between the two organizations to advance healthcare delivery in Singapore.
Mr Lawrence Loke, Group Chief Information Officer, SingHealth (left) and Jasper Westerink, Acting Managing Director, Philips APAC (right) sign on strategic partnership between the two organizations to advance healthcare delivery in Singapore.

This Memorandum of Understanding (MOU) inked between the two organizations signifies a significant step towards building a robust and standardized data architecture for SingHealth. By leveraging Philips state-of-the-art healthcare technologies, the partnership strives to enable seamless digital workflows and improve clinical decision-making. This allows care teams to enhance human interaction with patients, deepen connections and improve outcomes. This will advance SingHealth’s goal to deliver care in a more patient-centric manner through a digital-first strategy.

“We are privileged to partner with SingHealth on this venture to accelerate the digital transformation of healthcare delivery in Singapore,” said Hung Choong Hwang, Country Manager, Philips Singapore. “By combining our technological expertise with SingHealth’s clinical excellence, we aim to set new benchmarks in healthcare innovation, quality and resilience, in line with our vision of delivering better care for more people.”

Under the terms of the MOU, Philips and SingHealth will set up dedicated teams to drive three key projects over the course of three years, focused on integrating imaging data with AI, predictive data management to enable actionable insights and optimizing ICU capacities by boosting monitoring and patient assessment capabilities. As projects under the MOU progress, its potential scope may widen beyond these initial three projects to include other additional areas of collaboration where synergies and opportunities are identified by both parties.

Enhancing healthcare delivery with a digital-first approach through three key projects

1.  Getting the right information seamlessly to the right expert: Integrated imaging with AI embedded into workflows

This project will automate and streamline Enterprise Digital Image workflows, including acquisition, storage, distribution, retrieval and archival processes. By centralizing and modernizing the architecture for Radiology, Pathology, and other images for clinical practice, the project aims to standardize clinical access and enhance electronic medical records connectivity. Starting with Radiology, the project will also explore innovations such as the use of embedded AI to automate and integrate workflows.

2.  Supporting staff with clinical decision-making: Next-generation predictive enterprise data management

Next-generation data analytics will be deployed to provide real-time, actionable insights to sharpen clinical decision-making. With fully-integrated live stream clinical data as a foundation, the goal is to implement advanced device interface models and introduce programmable AI and visualization layers to support clinical care and enterprise storage. This capability, implemented at scale across the cluster, will be a springboard enabling SingHealth to develop more pioneering innovations in this space globally.

3.  Enhancing patient care with Smart ICU: Optimizing capacity based on patient acuity

New clinical decision support tools and advanced monitoring equipment will be used to optimize ICU capacity and enhance efficiency and care quality.

A unified monitoring system, aligned with clinical workflows such as alarm assessments, will be established. The infrastructure will be co-designed to achieve interoperability, ensure cloud and cybersecurity alignment, and support clinical workflow assessments. Additionally, AI-powered models and algorithms will be jointly developed to monitor developments in patients’ conditions, optimize alarm management, and deliver clinical parameter dashboards and avatars.

Partnerships key to future-proofing healthcare delivery with innovation

One of the key challenges in the complexities of the healthcare system is the ability to access and integrate different data sources to form a cohesive patient story. Accurate and timely access to data at critical points in a patient’s journey is key in the digital transformation of the healthcare system. According to the Singapore FHI 2024 report findings, more than one-third (37%) of healthcare leaders surveyed are looking to external partnerships to use data analytics for more informed decision-making.

Please refer to Annex for more info on Singapore findings of the Philips Future Health Index (FHI) 2024 report.

Philips has previously partnered SingHealth in the implementation of an iECG initiative to transform the delivery of cardiovascular care in Singapore. Philips also partnered Singapore General Hospital to advance its medical imaging capabilities.

“We believe in harnessing the power of strategic partnerships to address the unique healthcare needs of the Asia Pacific. By conducting thorough reviews of current capacities, processes and workflows, and thoughtfully integrating advanced technologies in a way that best supports staff, we are dedicated to improving healthcare outcomes and efficiency across this diverse and dynamic region,” said Jasper Westerink, Acting Managing Director, Philips APAC. “I’m excited about how our upcoming projects will positively impact patient care and digital healthcare innovation in the region, especially since SingHealth is Singapore’s largest healthcare group and has a track record of setting standards of excellence in patient-centred clinical care, and since Singapore is a key medical hub.”

Mr Lawrence Loke, Group Chief Information Officer, SingHealth, said, “This collaboration between SingHealth and Philips is a big stride forward in accelerating healthcare innovation in Singapore. By combining our deep and broad range of clinical expertise with Philips’ cutting-edge technology, we are prioritizing the needs of our patients in reimagining healthcare delivery. From ‘Smart ICUs’ to AI-driven diagnostics, our singular goal is to enhance patient outcomes and experiences. In our efforts to pilot transformative care models, we hope that our patients will receive personalized, timely and accessible care that is focused on achieving the best outcomes possible for them.”

As a key medical hub in the Asia Pacific, partnerships like these position Singapore well in leading the charge to pioneer and deploy next-generation healthcare technologies, driving efficiency, better care, and more accessible health services for more people across the region.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Annex

Addressing healthcare system challenges: Workforce, data and workflow optimization

With Singapore’s population set to become “super-aged” by 2026, and 21% of its population over the age of 65, the healthcare system faces mounting pressures.[1] According to the Singapore findings of the Philips Future Health Index (FHI) 2024 report, nearly two-thirds (65%) of healthcare leaders report that workforce shortages are leading to staff having less time with patients, higher patient-to-staff ratios and/or an increase in clinical errors. These challenges highlight the urgent need to augment clinical manpower and address growing patient workloads and demands on Singapore’s health services.

In addition to workforce shortages, healthcare leaders identified workflow prioritization as a key area for automation, which can help healthcare professionals better manage high patient volumes without compromising on care quality. For instance, automated initial screening of medical images can help prioritize cases and direct them to the right sub-specialty radiologist. Similarly, automated triaging systems can assist emergency department staff, improving efficiency and reducing strain on personnel.

Philips FHI 2024 report also revealed that 84% of Singapore’s healthcare leaders face data integration challenges, which hamper their ability to deliver timely, high-quality care. The inability to fully utilize data has wide-ranging effects, from financial and operational concerns to limiting coordination between clinicians and reducing their time spent with patients. Overcoming barriers to integrate data accessibly across clinical operations, human resources, and financials for reporting is therefore critical for continuous improvement, better decision-making and better patient empowerment.